Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Ellagic Ácid on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04011618
Recruitment Status : Recruiting
First Posted : July 8, 2019
Last Update Posted : November 17, 2020
Sponsor:
Collaborator:
National Council of Science and Technology, Mexico
Information provided by (Responsible Party):
Karina Griselda Pérez Rubio, University of Guadalajara

Brief Summary:
Metabolic syndrome (MS) is a group of important cardiovascular risk factors: abdominal obesity, dyslipidemia, hyperglycemia, and high blood pressure. Treatment requires the introduction of pharmacological management that includes different medications for each component. Ellagic acid (EA) is a polyphenol that has shown health benefits in multiple experimental studies. AE is consumed by patients without a prescription; considering there aren't studies that demonstrate it's effectiveness on MS, it is important to evaluate the possible effects of AE on this pathology. METHODOLOGY: Current study is a double-blind, placebo-controlled clinical trial. The aim of this study is evaluating the effect of AE on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Drug: Ellagic Acid / Pomegranate Extract Drug: Placebo oral capsule Phase 2

Detailed Description:
INTRODUCTION: Ellagic acid (EA) is a polyphenol that has shown health benefits in multiple experimental studies; mainly as an antioxidant, but also in hepatic steatosis, endothelial damage, hypertension, diabetes mellitus, visceral fat accumulation, dyslipidemia, insulin resistance, atherosclerosis, etc. There aren't studies that demonstrate the effectiveness of EA on MS; and since it is consumed by patients without any prescription, it is important to evaluate the effect of the administration of EA on the components of metabolic syndrome, insulin sensitivity, and insulin secretion. The current design is a randomized double-blind, placebo-controlled, clinical trial. METHODS: Male and female volunteers between 31 to 60 years of age, with MS diagnosis of MS according to the criteria of the International Diabetes Federation will be included, whether they accept participating and signing the informed consent. Patients with one or more of the following criteria will be excluded: History of liver, kidney, heart, or thyroid disease; systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, fasting blood glucose: ≥126 mg / dL, triglycerides ≥400 mg / dL, LDL cholesterol > 190 mg / dL; pregnancy or lactation; consumption of medications or supplements which interact with EA or that have effects on any of the components of the MS. Patients included, may be withdrawn from the study if they meet any of the following conditions: Withdrawal of the informed consent; compliance with some exclusion criteria during the study; treatment adherence <80%; intolerance to EC or placebo. OBJECTIVES: Main objectives are measuring and comparing before and after the intervention, the effect of EA or placebo on metabolic syndrome components, insulin sensitivity, and insulin secretion. HEADQUARTERS: The study will be carried out in the facilities of the Institute of Experimental and Clinical Therapeutics (INTEC), of the University Center of Health Sciences, in the University of Guadalajara. Guadalajara, Jalisco, Mexico.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-blind, placebo-controlled clinical trial
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: randomized double-blind
Primary Purpose: Treatment
Official Title: Effect of Ellagic Acid Administration on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Actual Study Start Date : September 17, 2019
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
16 patients to receive 1 homologated placebo capsule (calcinated magnesia 500 mg) every 12 hours along 12 weeks
Drug: Placebo oral capsule
Calcinated magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
Other Name: calcinated magnesia

Experimental: Ellagic acid
16 patients to receive 1 homologated intervention capsule (ellagic acid 500 mg) every 12 hours along 12 weeks
Drug: Ellagic Acid / Pomegranate Extract
Phenolic acid, ellagitannin, found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with ellagic acid 90% 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
Other Name: benzoaric acid




Primary Outcome Measures :
  1. waist circunference [ Time Frame: baseline to week 12 (end of intervention) ]
    Main criteria for metabolic syndrome diagnosis

  2. blood pressure [ Time Frame: baseline to week 12 (end of intervention) ]
    systolic blood pressure and diastolyc blood pressure by digital blood pressure monitor

  3. fasting blood glucose [ Time Frame: baseline to week 12 (end of intervention) ]
    fasting blood glucose by enzimatic-colorimetric automatized technique

  4. Fasting blood triglycerides concentration [ Time Frame: baseline to week 12 (end of intervention) ]
    fasting blood triglycerides by enzimatic-colorimetric automatized technique

  5. Fasting blood C-HDL concentration [ Time Frame: baseline to week 12 (end of intervention) ]
    fasting blood high density lypoprotein-cholesterol by enzimatic-colorimetric automatized technique

  6. Insulin sensitivity [ Time Frame: baseline to week 12 (end of intervention) ]
    From an oral glucose tolerance test with glucose 75g intake, and each 30 minutes sampling to get insulin and glucose levels; minuted glucose and insulin results will be analized with Matsuda Index to get insulin sensitivity

  7. Insulin secretion [ Time Frame: baseline to week 12 (end of intervention) ]
    Stumvoll and insulinogenic indexes will be used to calculating first-phase and total insulin secretion


Secondary Outcome Measures :
  1. body weight [ Time Frame: baseline to week 12 (end of intervention) ]
    body weight measured by bioelectrical impedance scale

  2. body mass index [ Time Frame: baseline to week 12 (end of intervention) ]
    body mass index (BMI) will be calculated with the Quetelet index formula

  3. body fat mass [ Time Frame: baseline to week 12 (end of intervention) ]
    body fat will be estimated by bioelectrical impedance analysis

  4. total cholesterol [ Time Frame: baseline to week 12 (end of intervention) ]
    fasting blood total cholesterol by enzimatic-colorimetric automatized technique

  5. Fasting blood C-LDL concentration [ Time Frame: baseline to week 12 (end of intervention) ]
    fasting blood low-density lipoprotein- cholesterol by enzimatic-colorimetric automatized technique

  6. Fasting blood VLDL concentration [ Time Frame: baseline to week 12 (end of intervention) ]
    fasting blood very low-density lipoprotein by enzimatic-colorimetric automatized technique

  7. Concentration of blood AST and ALT [ Time Frame: baseline / week 12 (end of intervention) ]
    aminotransferases by enzimatic-colorimetric automatized technique

  8. Concentration of blood uric acid [ Time Frame: baseline to week 12 (end of intervention) ]
    fasting blood uric acid by enzimatic-colorimetric automatized technique

  9. Concentration of blood creatinine [ Time Frame: baseline / week 12 (end of intervention) ]
    creatinine by enzimatic-colorimetric automatized technique

  10. Incidence of Treatment-Emergent Adverse Events [ Time Frame: baseline to week 12 (continuous surveillance) ]
    Incidence of placebo or ellagic acid, emergent adverse events will be identified by clinical evaluation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   31 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metabolic Syndrome diagnosis based on IDF criteria
  • Acceptance and signing of Informed Consent

Exclusion Criteria:

  • Knew kidney, liver, heart or thyroid disease
  • Systolic blood pressure ≥140 mmHg
  • Diastolic blood pressure ≥90 mmHg
  • Fast blood glucose ≥126 mg/dL
  • TG ≥400 mg/dL
  • C-LDL > 190 mg/dL
  • BMI: ≥35 kg/m2
  • Pregnancy or lactation period
  • Knew pomegranate allergy
  • Habitual warfarin, tolbutamide or carbamazepin consumption
  • Effect on any component of metabolic syndrome drugs or suplements regular intake

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04011618


Contacts
Layout table for location contacts
Contact: KARINA G PÉREZ-RUBIO, PhD +523310585200 ext 34212 karina2410@hotmail.com
Contact: MANUEL GONZÁLEZ-ORTIZ, PhD +523310585200 ext 34212 uiec@prodigy.net.mx

Locations
Layout table for location information
Mexico
INSTITUTO DE TERAPÉUTICA EXPERIMENTAL Y CLÍNICA. Centro Universitario de Ciencias de la Salud Recruiting
Guadalajara, Jalisco, Mexico, 44340
Contact: Karina G Pérez-Rubio, PhD    +523310585200 ext 34212    karina2410@hotmail.com   
Contact: Manuel González-Ortiz, PhD    +523310585200 ext 34212    uiec@prodigy.net.mx   
Sponsors and Collaborators
University of Guadalajara
National Council of Science and Technology, Mexico
Investigators
Layout table for investigator information
Principal Investigator: KARINA G PÉREZ-RUBIO, PhD University of Guadalajara
Layout table for additonal information
Responsible Party: Karina Griselda Pérez Rubio, Principal Investigator, University of Guadalajara
ClinicalTrials.gov Identifier: NCT04011618    
Other Study ID Numbers: Ellagic-SM
First Posted: July 8, 2019    Key Record Dates
Last Update Posted: November 17, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Karina Griselda Pérez Rubio, University of Guadalajara:
ellagic acid
metabolic syndrome
insulin resistance
insulin secretion
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Insulin Resistance
Syndrome
Disease
Pathologic Processes
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases